id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-5956-0007,FDA,FDA-2017-E-5956,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-17T04:00:00Z,2019,9,2019-09-17T04:00:00Z,,2019-09-17T14:10:30Z,,0,0,0900006483f873d0
FDA-2017-E-5956-0006,FDA,FDA-2017-E-5956,"Determination of Regulatory Review Period for Purposes of Patent
Extension; EUCRISA",Notice,Determinations,2019-02-12T05:00:00Z,2019,2,2019-02-12T05:00:00Z,2019-04-16T03:59:59Z,2019-02-12T13:43:07Z,2019-01956,0,0,0900006483a65f90
FDA-2017-E-5956-0005,FDA,FDA-2017-E-5956,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T18:18:30Z,,0,0,09000064839c09b4
FDA-2017-E-5956-0004,FDA,FDA-2017-E-5956,Letter from U.S. Patent and Trademark Office to  FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T16:48:16Z,,0,0,090000648378ce7b
FDA-2017-E-5956-0003,FDA,FDA-2017-E-5956,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-11-07T05:00:00Z,2017,11,2017-11-07T05:00:00Z,,2017-11-07T14:31:37Z,,0,0,0900006482c545bf
FDA-2017-E-5956-0001,FDA,FDA-2017-E-5956,Patent Extension Application from Pfizer Inc.,Other,Application,2017-09-27T04:00:00Z,2017,9,2017-09-27T04:00:00Z,,2017-09-27T18:02:18Z,,0,0,0900006482b8398b
FDA-2017-E-5956-0002,FDA,FDA-2017-E-5956,U.S. Patent and Trademark Office,Other,Letter(s),2017-09-27T04:00:00Z,2017,9,2017-09-27T04:00:00Z,,2017-09-27T18:07:17Z,,0,0,0900006482b8398e